Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment for multiple sclerosis.
24/7 Wall St. has picked a few biotech standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Los hospitales de hoy en día son lugares de esperanza e innovación. Están muy lejos de ser las instituciones de principios del siglo XX, con condiciones insalubres y pacientes en su mayoría...
Atara Biotherapeutics shares dipped on Thursday after the company provided a few business updates.
Atara Biotherapeutics shares surged on Friday after the firm announced that it received clearance from the FDA to initiate two Phase 3 clinical studies.
The top analyst upgrades, downgrades and initiations for Monday included Aimmune Therapeutics, Apple, Aurora Cannabis, Dick's Sporting Goods, Halliburton, HP, JPMorgan, Lowe's, Lyft, Schlumberger and...
Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it is important to understand that there is a much larger risk when an analyst calls for such...
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ariad Pharmaceuticals, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M and Time Warner.
Tuesday's top analyst calls were in shares of Albermarle, Atara Biotherapeutics, Chimerix, IHS, NetApp, Pure Storage and more.
Dan Popadynec se inspiró en una pregunta inusual que le hizo su hijo Zennon: el niño preguntó al ingeniero profesional licenciado si sabía cuál era la altura de la torre de juguetes más alta...
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting in patients with end stage renal disease.
24/7 Wall St. has tracked four companies in which shareholders were destroyed last week. Many of these companies have seen their markets caps drop sharply.
Atara Biotherapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).